Barclays raised the firm’s price target on Amgen to $230 from $210 and keeps an Underweight rating on the shares. The analyst says U.S. Biopharma enters the Q3 earnings season “with still widely negative sentiment.” The firm is “positively-biased” into the Q3 setups against a backdrop of solid script trends, poor sentiment, and “idiosyncratic” headwinds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- FDA Oncologic Drugs Advisory Committee holds virtual meeting
- BCBSM modifying weight loss drug coverage to require ‘lifestyle modifications’
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Amgen price target raised to $280 from $260 at Argus
- Amgen presents new LUMAKRAS plus chemotherapy data in first-line KRAS G12C NSCLC